Development and optimization of a tamsulosin nanostructured lipid carrier loaded with saw palmetto oil and pumpkin seed oil for treatment of benign prostatic hyperplasia

• Published in: Drug delivery 2022-12, Vol.29 (1), p.2579-2591
• Main Authors: Bakhaidar, Rana B., Hosny, Khaled M., Mahier, Imman M., Rizq, Waleed Y., Safhi, Awaji Y., Bukhary, Deena M., Sultan, Muhammad H., Bukhary, Haitham A., Madkhali, Osama A., Sabei, Fahad Y.
• Format: Article
• Language: English
• Subjects: drug delivery system; Drug delivery systems; experimental design; Fatty acids; Genital diseases; Hyperplasia; Lipids; nanoparticle; Nanoparticles; Pharmaceutical sciences; Pharmacokinetics; Pharmacy; Prostate; prostate index; Quality of life; Seeds; Tamsulosin; Urogenital system
• ISSN: 1071-7544; 1521-0464
• DOI: 10.1080/10717544.2022.2105448

Benign prostatic hyperplasia (BPH) is a nonmalignant growth of the prostate tissue and causes urinary tract symptoms. To provide effective treatment, tamsulosin (TM), saw palmetto oil (SP), and pumpkin seed oil (PSO) were combined and fabricated a nanostructured lipid carrier (NLC) as TM-S/P-NLC using experimental design. The purpose was to enhance the permeation and therapeutic activity of TM; combining TM with SP and PSO in an NLC generates a synergistic activity. An optimized TM-S/P-NLC was obtained after statistical analysis, and it had a particle size, percentage of entrapment efficiency, and steady-state flux of 102 nm, 65%, and 4.5 μg/cm 2 .min, respectively. Additionally, the optimized TM-S/P-NLC had spherical particles with a more or less uniform size and a stability score of 95%, indicating a high level of stability. The in vitro release studies exhibited the optimized TM-S/P-NLC had the maximum release profile for TM (81 ± 4%) as compared to the TM-NLCs prepared without the addition of S/P oil (59 ± 3%) or the TM aqueous suspension (30 ± 5%). The plasma TM concentration-time profile for the TM-S/P-NLC and the marketed TM tablets indicated that when TM was supplied in a TM-S/P-NLC, the pharmacokinetic profile of the drug was improved. Simultaneously, in vivo therapeutic efficacy studies also showed favorable results for the TM-S/P-NLC in terms of the prostate weight and prostate index following treatment of BPH. Based on the findings of present study, we suggest that in the future, the TM-S/P-NLC could be a novel drug delivery system for treating BPH.